Biotricity Inc represents a commitment to revolutionizing healthcare through innovative medical technology. The company's core values include a dedication to patient-centered care, a focus on continuous improvement, and a passion for advancing remote monitoring solutions. Biotricity Inc's corporate philosophy revolves around providing personalized, data-driven healthcare solutions that empower individuals and healthcare providers alike. With a strong emphasis on technological development and exceptional patient outcomes, Biotricity Inc is at the forefront of transforming healthcare through their cutting-edge remote monitoring devices and services.

Biotricity Inc is primarily present in the United States.

Biotricity Inc has achieved significant milestones in its journey. The company has successfully developed and launched its remote monitoring solutions for various healthcare applications. Biotricity's flagship product, Bioflux, an FDA-cleared remote cardiac monitoring system, has paved the way for advanced arrhythmia detection and personalized patient care. The company's commitment to innovation has also led to the development of BiofluxPRO, a cloud-based platform that integrates patient data, enhancing healthcare professionals' ability to make timely and accurate diagnoses. Biotricity's dedication to advancing digital health solutions and improving patient outcomes sets it apart in the industry.

Biotricity Inc is a leading medical technology company specializing in remote monitoring solutions for chronic diseases. Founded in 2015, the company aims to revolutionize the healthcare industry by providing innovative wearable devices and data analytics platforms. Biotricity Inc's history showcases its commitment to improving patient outcomes through advanced patient monitoring technology. With a focus on personalized and preventative care, Biotricity Inc strives to empower patients and medical professionals in managing chronic conditions more effectively. By leveraging cutting-edge technology, Biotricity Inc aims to enhance patient lives and contribute to the overall advancement of healthcare.

The main competitors of Biotricity Inc in the market are Medtronic, Inc., Abbott Laboratories, and Philips Healthcare.

Biotricity Inc is primarily active in the healthcare and medical technology industries.

The business model of Biotricity Inc. revolves around developing and providing innovative remote monitoring solutions for chronic diseases and healthcare providers. Biotricity aims to deliver personalized and cost-effective remote monitoring tools to empower patients and improve healthcare outcomes. By leveraging advanced technology and data analytics, Biotricity's monitoring solutions enable physicians to track patients' vitals remotely, facilitating proactive intervention and customized treatment plans. As a leader in the digital health industry, Biotricity focuses on enhancing patient care through its cutting-edge biomedical devices and cloud-based platform, ultimately revolutionizing the way healthcare is delivered.

Biotricity hissesinin F/K oranı -0,19.

Biotricity KUV 0,24 dir.

Biotricity için AlleAktien Kalite Skoru 7/10'dur.

Biotricity cirosu 12,06 Milyon. USD dir.

Biotricity karı -14,93 Milyon. USD olarak gerçekleşmiştir.

Biotricity Inc. is a company specializing in the development and marketing of products in the field of digital health monitoring. The company's business model focuses on providing solutions for monitoring heart health and treating chronic diseases such as diabetes and high blood pressure, among others. Biotricity offers a variety of products and services tailored to the needs of patients, doctors, and hospitals. Key products include monitoring systems such as Bioflux and Biocentrix, which are capable of measuring various vital functions including EKG, respiration, oxygen saturation, and blood sugar. An important aspect of Biotricity's business model is telemedicine, which allows doctors and healthcare professionals to remotely monitor and treat patients. The Bioflux platform, for example, provides automated monitoring of heart conditions to inform doctors of deviations from the normal state in real-time. The Biocentrix platform is a digital health solution that enables automated monitoring of diabetes and high blood pressure. Another important aspect of Biotricity's business model is the integration of artificial intelligence and machine learning into its products and services. For example, the Bioflux platform can analyze data and detect patterns to make predictions about the risk of heart attacks and other diseases. The integration of artificial intelligence into health monitoring could play a crucial role in improving the accuracy of diagnoses and therapies in the future. Biotricity also pursues a strategic partnership strategy to place its products and services in the market. A partnership with ReliantHeart, Inc. and Blackford County Hospital aims to expand Biotricity's business in the areas of telemedicine and home monitoring. Biotricity's product range also includes "smart shirts" equipped with sensors that can measure respiration and heart rate. These wearables provide an alternative way to monitor cardiovascular health and can be comfortably worn in everyday life. Overall, Biotricity aims to expand the role of telemedicine and wearables in patient monitoring by integrating innovative products and services with artificial intelligence and machine learning. The goal is to improve the diagnosis and management of chronic diseases while facilitating access to healthcare. Please write your answer feedback in the output.

Biotricity, yılda kez dağıtılmak üzere 0,16 USD tutarında temettü ödemektedir.

Biotricity için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Biotricity şirketinin ISIN kodu US09074H1041’dir.

Biotricity 'nin WKN'si A2DWS9 'dir.

Biotricity için Ticker BTCY’dir.

Son 12 ay içerisinde Biotricity, 0,16 USD tutarında bir temettü ödedi. Bu, yaklaşık olarak 49,06 % oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Biotricity, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Biotricity şirketinin mevcut temettü verimi 49,06 %.

Biotricity dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Biotricity, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Biotricity, 'Sağlık' sektörüne atanmıştır.

Son Biotricity tarihinde 0,079 USD tutarındaki en son temettüyü alabilmek için, hisseyi 23.02.2022 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 07.03.2022 olarak gerçekleşti.

2023 yılında Biotricity tarafından 0,157 USD olarak temettüler dağıtıldı.

Biotricity hisselerinin temettüleri USD olarak dağıtılır.